Concepedia

Sandra Hadl

SH

Statistics

Publications

4

Citations

281

H-Index

4

Active since

2023

Affiliations

Valneva (Austria)(Current)

University of Applied Sciences Burgenland

Sandra Hadl is an author at Valneva (Austria) specializing in medicine, vaccine development, and vaccine safety.

Top concepts

Publications per year

2023–2024

4

Publications

4

Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial

Martina Schneider, Marivic Narciso-Abraham, Sandra Hadl et al. · The Lancet · 2023 · 192 citations · Full text

A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults

Robert P. McMahon, Ulrike Fuchs, Martina Schneider et al. · Journal of Travel Medicine · 2023 · 32 citations · Full text

Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study

Robert P. McMahon, Sebastian Toepfer, Natascha Sattler et al. · The Lancet Infectious Diseases · 2024 · 29 citations

, , +7

Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents

Vera Buerger, Sandra Hadl, Martina Schneider et al. · The Lancet Infectious Diseases · 2024 · 28 citations

, , +8

1–4 of 4